ATL1102 Antisense and Multiple Sclerosis, page-3

There had been queries over dosing levels in prior years.
We were negotiating with the FDA to progress MS trials at a pertinent level which required some maneuvering. 200mg was higher than they were comfortable with.
DMD came along and suggested it was the indication that showed good potential and the most affordable pathway to success. so MS was put on the back burner because it required additional funding to progress it, and DMD was appealing to larger investors for more immediate return.
DMD data is now a tool to be utilised also for MS to show varying ATL-1102 dosing levels and the safety confirmations.
So, DMD trials are obviously helping DMD and hopefully benefitting progression for MS also.
Funding from anything large, whether it be DMD, Acromelagy, new indications or even Capital Raising in the future can be used to reignite MS or Acromegaly, or partner or licencing deals can have the same effect.
ATL-1102 for MS is just waiting for circumstances to alter. I think it should be an important part of ANP in the future.